Outcomes | Anticipated absolute effects*(95% CI) | Relative effect(95% CI) | № of participants (studies) | Certainty of the evidence(GRADE) | Comments | |
---|---|---|---|---|---|---|
Risk with placebo | Risk with galcanezumab | |||||
Reduction of monthly migraine days follow up: 3 months | The mean reduction of monthly headache days was −2.7 days | The mean reduction of monthly headache days in the intervention group was 1.9 days lower (2.7 lower to 1.1 lower) | – | 835(1 RCT) | ⨁⨁⨁◯MEDIUMa | Treatment with Galcanezumab 240 mg reduces monthly migraine days slightly compared to placebo. |
Reduction of monthly acute treatment days follow up: 3 months | The mean reduction of monthly headache days was −2.2 days | The mean reduction of monthly acute treatment days in the intervention group was 2.0 days lower (2.8 lower to 1.3 lower) | – | 835(1 RCT) | ⨁⨁⨁◯MEDIUMa | Treatment with Galcanezumab 240 mg reduces monthly acute treatment days slightly compared to placebo. |
Improvement in functional MIDAS score follow up: 3 months | The mean improvement in functional MIDAS score was −11.5 points | The mean improvement in functional MIDAS score in the intervention group was 5.5 points lower (13.1 lower to 2.1 higher) | – | 835(1 RCT) | ⨁⨁⨁◯MEDIUMa | Treatment with Galcanezumab 240 mg does not improve functional MIDAS score significantly compared to placebo. |
At least 50% reduction of monthly migraine days follow up: 3 months | 149 per 1000 | 285 per 1000(216 to 377) | RR 1.9181(1.4531 to 2.5321) | 835(1 RCT) | ⨁⨁⨁◯MEDIUMa | Treatment with Galcanezumab 240 mg mg results in at least 50% reduction of monthly headache days compared to placebo. |
Serious adverse events follow up: 3 months | 7 per 1000 | 19 per 1000(5 to 70) | RR 2.6534(0.7181 to 9.8049) | 835(1 RCT) | ⨁⨁⨁◯MEDIUMa | Treatment with Galcanezumab 240 mg mg results in a possibly unimportant effect on serious adverse event occurrence compared to placebo. |
Mortalityfollow up: 3 months | 0 per 1000 | 0 per 1000(0 to 0) | not estimable | 835(1 RCT) | No deaths were observed with treatment with Galcanezumab 240 mg or placebo |